news

Breakthrough for mosquito virus outbreaks

A team of researchers are developing ways to treat debilitating diseases caused by alphaviruses such as Chikungunya and Ross River virus…

virus

A team of researchers are developing ways to treat debilitating diseases caused by alphaviruses such as Chikungunya and Ross River virus, the researchers have discovered a way that could help treat severe inflammation from an infectious mosquito-borne disease during outbreaks.

“When we infected mice with Chikungunya, we found that a type of inflammasome known as NLRP3 was activated, which triggered an inflammatory cascade, leading to severe joint inflammation and bone damage,” said Dr Ali Zaid, a lead author of the study.

“So we used a molecule which specifically inhibits the activation of NLRP3, and we found that it helped reduce Chikungunya inflammation in mice, and also helped reduce bone loss and muscle inflammation. “We found the same in mice infected with Ross River virus.

Targeting the inflammasome using this kind of drug could be an efficient way to treat patients suffering from acute Chikungunya or Ross River virus disease during outbreaks,” Dr Zaid added.

Collaborator Professor Matt Cooper from the Institute of Molecular Bioscience at the University of Queensland said, “By precisely modulating how our immune system responds to infection, we hope to develop new therapies that can be used to treat people with these serious diseases”

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

Professor Suresh Mahalingam said the findings were important as inflammasome NLRP3 was prominently expressed in CHIKV patients with severe disease. “The NLRP3 inhibitor drug, MCC950, provided significant amelioration of inflammation and disease in CHIKV-infected mice. The drug provided these therapeutic benefits without compromising antiviral immunity.”

The research has been published in the journal Nature Microbiology.

Leave a Reply

Your email address will not be published. Required fields are marked *